We are thrilled to congratulate the UCB BIMZELX Dermatology HCP Marketing Team from UCB on being selected as an ELITE100 Marketing Team! Don’t miss a chance to meet them and all of our other incredible ELITE winners tomorrow on June 18th at 230 FIFTH Rooftop in NYC for our celebration of the pharma industry’s best and brightest: https://lnkd.in/g4nE39eW
PM360 Magazine’s Post
More Relevant Posts
-
Insights into the Pharma Dermatology Market – MAT May 2024. We're excited to share our latest analysis of the Pharma Dermatology market. Know the top-performing molecules and regions driving significant growth in this sector. Highlights include: - Key molecules showing impressive market growth - Regions leading in dermatology sales performance - In-depth market trends and data-driven insights Swipe through the slides to gain a deeper understanding of the market dynamics and discover the factors influencing these trends. Read complete report for MAT May 24' in https://lnkd.in/duRnrJJh Data set: MAT May 2024. #Pharmarack #PharmaDermatology #PharmaInsights #DermatologyTrends #PharmaIndustry
To view or add a comment, sign in
-
NEW Live Webinar – Acne Vulgaris Therapeutic Update: Overview of the 2024 Treatment Guidelines on May 30th. Over 50 million people in the US have acne, leading to $846 million in medical costs and $398 million in lost productivity. This live webinar will review acne vulgaris and its clinical features along with summarizing the 2024 American Academy of Dermatology Guidelines for this condition. Register Now - https://bit.ly/3JHDto4 FACULTY - Darrell Hulisz, RPh, PharmD #pharmacists #pharmacytechnicians #continuingeducation #livewebinar
To view or add a comment, sign in
-
-
Gave a talk at Northeast Dermatology Conference on “A practical approach to using JAK inhibitors in dermatology”. Thanks for the great turnout! - via #Whova event app My 3-step approach to discussing the “boxed warning” : 1) NORMALIZE the boxed warning: we have a lot of medications in dermatology, including OTC, that also contain a boxed warning, but we continue to use these medications with regularity because we understand the context behind them. 2) CONTEXTUALIZE the boxed warning: different drugs, different diseases, different demographics WITHOUT a placebo group. This last point is crucial as we can interpret the ORAL surveillance study in 3 ways: A) Risk: JAKi > no treatment > TNFi B) Risk: JAKi = no treatment > TNFi C) Risk: no treatment > JAKi > TNFi *Time will tell but we also have to acknowledge that not treating/undertreating a disease has negative downstream effects as well. 3) REFERENCE long-term extension (which admittedly have limitations) and real world studies to show the incidence rates in patients who have AD but are not treated with a JAK inhibitor vs those who are treated with a JAK inhibitor. Spoiler alert: not much of an appreciable difference.
To view or add a comment, sign in
-
-
Pharmacists and pharmacy technicians are often the first point of contact for patients seeking guidance on OTC skin care products. As such, it's essential that they're equipped to provide accurate and up-to-date information on dermatological health and protection. Check out the resource center at Pharmacy Times Continuing Education™ (PTCE) on optimizing skin care and outcomes in skin conditions through OTC options. The webinars also cover the current American Academy of Dermatology guidelines for managing and treating these conditions. The 5 activities in this webinar curriculum demonstrate commitment to improving patient education and identifying potential triggers, as well as recommending therapies to effectively manage these conditions while restoring and maintaining the skin barrier function. Crystal Yu, PharmD CeraVe
To view or add a comment, sign in
-
-
Medical Doctor at Sancta Maria Hospital Swansea and Independent GP Cardiff, Clinician at 1192 Laser & Beauty Clinic. Specialise in Menopause, Women’s Health, Aesthetic Medicine, Elderly Care, Youth Clinics, Sexual Health
@aadmember According to a study published in the Journal of Drugs in Dermatology, platelet-rich plasma (PRP) therapy may be more effective than minoxidil in treating androgenetic alopecia (AGA). In this randomized controlled trial, the investigators evaluated the efficacy of PRP vs. 5% topical minoxidil for the treatment of AGA in 72 patients from a single institution. Patients were treated with either therapy for 12 weeks. At the beginning of the trial, the average hair count per patient in the PRP group was 83.5 ‡ 39.63 hairs/cm2 and the average hair count in the minoxidil group was 88.94 ‡ 36.09 hairs/cm2. All patients were positive for hair pull tests. After 12 weeks of treatment, hair pull tests were negative for 91.7% of the PRP group and 69.4% of the minoxidil group. The authors conclude that PRP therapy demonstrated a higher efficacy compared to minoxidil for treating AGA. 1192 Laser & Beauty Clinic Swansea.com Stadium #plateletrichplasma #prp #minoxidil #alopeciatreatment #hairloss
To view or add a comment, sign in
-
-
Dermatology Times is beginning to shape a guide to 2024's summer and early fall dermatologic conferences and meetings. What conferences are you planning to attend between July and September? Share with us below. ⬇️ https://lnkd.in/ggmSnFQG
To view or add a comment, sign in
-
An important read for anyone living with dermatological conditions and dermatology healthcare providers/stakeholders. Please share widely and fill out the survey and contribute to improving the lives of folks with skin conditions. Take the survey at https://lnkd.in/gH_HY2-a - Available in 17 different languages #globalskin #griddstudy #dermatology #lichensclerosus #lichenplanus #gynecology #researchstudy #vitiligo #substanceuselymphoma #hyperhidrosis #lupus #naevusflammeus #myosotis #albinism #psoriasis #ezcema
Dermatology stakeholders, GlobalSkin seeks your support! Our GRIDD Study aims to collect global data on the impact of dermatological conditions on patients' lives. Encourage your patient networks to take part in our 10–20-minute survey. Use our toolkit for effective outreach: https://lnkd.in/eE3A4h77. This is your chance to ensure that country-specific issues and challenges faced by dermatology patients within your network are adequately captured in the study. The survey is open until Sept. 28 and available in 17 languages. https://lnkd.in/gkEyNjmk #GRIDDStudy #ResearchStudy #vitiligo #atopicdermatitis #hyperhidrosis #lichenplanus #lupus #naevusflammeus #myosotis
To view or add a comment, sign in
-
-
Earlier this month, Clario was at #ISPOR2024 in Atlanta and presented two scientific posters. For those of you who missed them, below are a few takeaways. Compliance and Design Features of Electronic Participant-Reported Dosing Diaries 1) More consistency is needed in the types of questions dosing diaries include and standardization of requirements to support data quality. 2) High compliance over time and across studies with dosing diaries supports the use of eDiaries as an indicator for drug adherence. Electronic Collection of PRO Measures in Dermatology Trials 1) ePROs are common in dermatology trials and are targeted as primary and key secondary endpoints in successful FDA approvals. 2) Clario has successfully supported electronic collection of PROs in dermatology trials for primary and key secondary endpoints. For any questions on how to optimize your dosing diary or dermatology trial using ePROs, please contact [email protected] #sciencematters #ePRO #ediaries
To view or add a comment, sign in